S&P 500   3,377.00 (-0.10%)
DOW   27,886.22 (-0.32%)
QQQ   272.87 (+0.37%)
MSFT   209.58 (+0.19%)
FB   260.76 (+0.33%)
GOOGL   1,509.00 (+0.12%)
AMZN   3,178.71 (+0.52%)
NVDA   460.28 (+0.58%)
TSLA   1,615.00 (+3.87%)
ACB   9.69 (-1.12%)
NFLX   477.14 (+0.35%)
BA   174.00 (-0.82%)
S&P 500   3,377.00 (-0.10%)
DOW   27,886.22 (-0.32%)
QQQ   272.87 (+0.37%)
MSFT   209.58 (+0.19%)
FB   260.76 (+0.33%)
GOOGL   1,509.00 (+0.12%)
AMZN   3,178.71 (+0.52%)
NVDA   460.28 (+0.58%)
TSLA   1,615.00 (+3.87%)
ACB   9.69 (-1.12%)
NFLX   477.14 (+0.35%)
BA   174.00 (-0.82%)
S&P 500   3,377.00 (-0.10%)
DOW   27,886.22 (-0.32%)
QQQ   272.87 (+0.37%)
MSFT   209.58 (+0.19%)
FB   260.76 (+0.33%)
GOOGL   1,509.00 (+0.12%)
AMZN   3,178.71 (+0.52%)
NVDA   460.28 (+0.58%)
TSLA   1,615.00 (+3.87%)
ACB   9.69 (-1.12%)
NFLX   477.14 (+0.35%)
BA   174.00 (-0.82%)
S&P 500   3,377.00 (-0.10%)
DOW   27,886.22 (-0.32%)
QQQ   272.87 (+0.37%)
MSFT   209.58 (+0.19%)
FB   260.76 (+0.33%)
GOOGL   1,509.00 (+0.12%)
AMZN   3,178.71 (+0.52%)
NVDA   460.28 (+0.58%)
TSLA   1,615.00 (+3.87%)
ACB   9.69 (-1.12%)
NFLX   477.14 (+0.35%)
BA   174.00 (-0.82%)
Log in

NASDAQ:SYBXSynlogic Stock Price, Forecast & News

$2.40
+0.04 (+1.69 %)
(As of 08/13/2020 09:36 AM ET)
Add
Compare
Today's Range
$2.37
Now: $2.40
$2.60
50-Day Range
$1.85
MA: $2.13
$2.40
52-Week Range
$1.35
Now: $2.40
$5.25
Volume489,500 shs
Average Volume365,989 shs
Market Capitalization$82.00 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Read More
Synlogic logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYBX
CUSIPN/A
Phone617-401-9975

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.22 million
Book Value$4.86 per share

Profitability

Net Income$-51,370,000.00
Net Margins-2,761.83%

Miscellaneous

Employees74
Market Cap$82.00 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$2.40
+0.04 (+1.69 %)
(As of 08/13/2020 09:36 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYBX News and Ratings via Email

Sign-up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synlogic (NASDAQ:SYBX) Frequently Asked Questions

How has Synlogic's stock price been impacted by COVID-19 (Coronavirus)?

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYBX stock has increased by 55.8% and is now trading at $2.40.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Synlogic?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Synlogic
.

When is Synlogic's next earnings date?

Synlogic is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Synlogic
.

How were Synlogic's earnings last quarter?

Synlogic Inc (NASDAQ:SYBX) released its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02. Synlogic had a negative return on equity of 36.85% and a negative net margin of 2,761.83%.
View Synlogic's earnings history
.

When did Synlogic's stock split? How did Synlogic's stock split work?

Synlogic's stock reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SYBX?

5 Wall Street analysts have issued 1 year target prices for Synlogic's stock. Their forecasts range from $2.00 to $13.00. On average, they expect Synlogic's stock price to reach $7.33 in the next twelve months. This suggests a possible upside of 205.6% from the stock's current price.
View analysts' price targets for Synlogic
.

Has Synlogic been receiving favorable news coverage?

News articles about SYBX stock have trended extremely negative on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Synlogic earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Synlogic
.

Are investors shorting Synlogic?

Synlogic saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 353,100 shares, an increase of 7.2% from the July 15th total of 329,400 shares. Based on an average daily volume of 338,600 shares, the short-interest ratio is presently 1.0 days. Currently, 1.9% of the shares of the stock are sold short.
View Synlogic's Short Interest
.

Who are some of Synlogic's key competitors?

What other stocks do shareholders of Synlogic own?

Who are Synlogic's key executives?

Synlogic's management team includes the following people:
  • Dr. Peter Barrett, Exec. Chairman (Age 66)
  • Dr. José Carlos Gutierrez-Ramos, Advisor (Age 56)
  • Dr. Aoife M. Brennan MB, BCh, BAO, MMSc, Pres, CEO, Chief Medical Officer & Director (Age 43)
  • Prof. Timothy K. Lu, Co-Founder
  • Dr. James J. Collins, Co-Founder

What is Synlogic's stock symbol?

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Who are Synlogic's major shareholders?

Synlogic's stock is owned by a variety of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.25%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea.
View institutional ownership trends for Synlogic
.

Which major investors are selling Synlogic stock?

SYBX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp.
View insider buying and selling activity for Synlogic
.

Which major investors are buying Synlogic stock?

SYBX stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc..
View insider buying and selling activity for Synlogic
.

How do I buy shares of Synlogic?

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Synlogic's stock price today?

One share of SYBX stock can currently be purchased for approximately $2.40.

How big of a company is Synlogic?

Synlogic has a market capitalization of $82.00 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe.

What is Synlogic's official website?

The official website for Synlogic is www.synlogictx.com.

How can I contact Synlogic?

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.